Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

序号38 药代动力学 医学 伊立替康 喜树碱 抗体 药理学 不利影响 结合 中性粒细胞减少症 活性代谢物 间隙 内科学 胃肠病学 毒性 免疫学 癌症 泌尿科 化学 生物化学 数学分析 结直肠癌 数学
作者
Allyson J. Ocean,Alexander Starodub,Aditya Bardia,Linda T. Vahdat,Steven Jay Isakoff,Michael J. Guarino,Wells A. Messersmith,Vincent J. Picozzi,Ingrid A. Mayer,William A. Wegener,Pius P. Maliakal,Serengulam V. Govindan,Robert M. Sharkey,David M. Goldenberg
出处
期刊:Cancer [Wiley]
卷期号:123 (19): 3843-3854 被引量:246
标识
DOI:10.1002/cncr.30789
摘要

BACKGROUND: Sacituzumab govitecan (IMMU-132), an antitrophoblastic cell-surface antigen (anti-Trop-2) humanized antibody-SN-38 conjugate, had encouraging efficacy in the phase 1 clinical trial. This report further examines the pharmacokinetics and safety of multiple cycles of IMMU-132 at doses of 8 or 10 mg/kg in patients with diverse advanced epithelial cancers. METHODS: Patients who had multiple prior therapies received IMMU-132 on days 1 and 8 of 21-day treatment cycles. Trop-2 staining of archived tumor specimens, clearance of IMMU-132 and its constituents (ie, immunoglobulin G [IgG], SN-38 [a camptothecin, the active component of irinotecan], and glucuronidated SN-38 [SN-38G]), antibody responses, and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) levels were determined. Safety was assessed according to Common Terminology Criteria for Adverse Events version 4.0, and responses were assessed using Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: Patients with diverse metastatic cancers who received IMMU-132 at 8 mg/kg (n = 81) and 10 mg/kg (n = 97) were examined. Trop-2 was positive in 93% of the available specimens. IMMU-132 cleared with a half-life of approximately 11 to 14 hours, reflecting the release of SN-38 from the conjugate; IgG cleared more slowly (half-life, approximately 103-114 hours). Most SN-38 in the serum (>95%) was bound to IgG. SN-38G concentrations were lower than SN-38 concentrations. Dose-limiting neutropenia after the first cycle was not correlated with SN-38 in serum or with UGT1A1 genotype. No antibody responses were detected. Objective responses were observed in several indications, including metastatic triple-negative breast cancer, confirming that 10 mg/kg produced an encouraging overall response. CONCLUSIONS: Sacituzumab govitecan has a predictable pharmacokinetic profile and manageable toxicity at doses of 8 and 10 mg/kg. With objective responses and a good therapeutic index at 10 mg/kg, this dose was chosen for future development. Cancer 2017;123:3843-3854. © 2017 American Cancer Society.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
滴答滴答完成签到,获得积分10
刚刚
Qq完成签到,获得积分10
1秒前
1秒前
溜溜梅发布了新的文献求助10
1秒前
Raymond完成签到,获得积分0
2秒前
辛勤诗兰完成签到,获得积分10
2秒前
3秒前
3315152548完成签到,获得积分10
3秒前
3秒前
3秒前
3秒前
3秒前
CMUSK完成签到,获得积分10
3秒前
路星辞完成签到 ,获得积分10
3秒前
饱满雁玉完成签到,获得积分10
3秒前
Owen的应助被plabs采纳,获得10
3秒前
李j1完成签到,获得积分10
4秒前
如影随形完成签到,获得积分10
4秒前
沉静秋尽完成签到,获得积分10
4秒前
springlrt的应助被隐形的迎南采纳,获得20
4秒前
5秒前
5秒前
5秒前
5秒前
程程程完成签到,获得积分20
5秒前
caoshijuan发布了新的文献求助10
5秒前
TangDing完成签到,获得积分10
6秒前
6秒前
ly发布了新的文献求助10
6秒前
7秒前
7秒前
爆米花的应助被zzjjss采纳,获得10
7秒前
7秒前
张楠发布了新的文献求助10
7秒前
今后的应助被无我采纳,获得10
8秒前
zzz完成签到,获得积分10
8秒前
呆妞发布了新的文献求助10
8秒前
泡泡发布了新的文献求助10
8秒前
冷静汉堡完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159929
求助须知:如何正确求助?哪些是违规求助? 9555266
关于积分的说明 21726335
捐赠科研通 7749807
什么是DOI,文献DOI怎么找? 3427310
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471654